International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C

Journal of Hepatology

Volumn 43, Issue 2, 2005, Pages 250-257

  Zeuzem, Stefan ^a   Pawlotsky, Jean Michel ^b   Lukasiewicz, Esther ^c   Von Wagner, Michael ^a   Goulis, Ioannis ^d   Lurie, Yoav ^e   Gianfranco, Elia ^f   Vrolijk, Jan Maarten ^g   Esteban, Juan I ^h   Hezode, Christophe ^b   Lagging, Martin ⁱ   Negro, Francesco ^j   Soulier, Alexandre ^b   Verheij Hart, Elke ^g   Hansen, Bettina ^g   Tal, Ronen ^c   Ferrari, Carlo ^f   Schalm, Solko W ^g   Neumann, Avidan U ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b HENRI MONDOR HOSPITAL   (France)

^c BAR ILAN UNIVERSITY   (Israel)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

HCV RNA quantification; Hepatitis C virus; Histamine; Pegylated interferon; Ribavirin; Viral kinetics

Indexed keywords

HISTAMINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANXIETY; APPENDICITIS; ARTICLE; ASTHENIA; BRAIN INFARCTION; CHORIORETINITIS; CLASSIFICATION; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; GASTROENTERITIS; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; ILEUS; INTERMETHOD COMPARISON; KIDNEY COLIC; KIDNEY FAILURE; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; PHARYNGITIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; SIDE EFFECT; STANDARDIZATION; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; VIOLENCE; VIRUS ATTENUATION; VISUAL IMPAIRMENT;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SAFETY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 21844477610     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.05.016     Document Type: Article

References (19)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. S.J. Hadziyannis, H. Sette Jr, T. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon alfa-2a (40 kD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
4. EASL International Consensus Conference on hepatitis C Consensus statement J Hepatol 31 1999 3 8
5. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology 2002; 36 p. S3-S15.
6. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, and T.J. Layden Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
7. S. Zeuzem, E. Herrmann, J.H. Lee, J. Fricke, A.U. Neumann, and M. Modi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a Gastroenterology 120 2001 1438 1447
8. S.J. Pocock Allocation of patients to treatment in clinical trials Biometrics 35 1979 183 197
9. A.U. Neumann, N.P. Lam, H. Dahari, M. Davidian, T.E. Wiley, and B.P. Mika Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus J Infect Dis 182 2000 28 35
10. J-P. Bronowicki, D. Ouzan, A. Tzanck, T. Asselah, H. Desmorat, and J-P. Zarski Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a (40 KD) alone versus peginterferon alfa-2a (40 KD) plus ribavirin in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2a (40 KD) plus ribavirin: an open, multicenter, randomized trial Hepatology 38 2003 244 245
11. S. Zeuzem, R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, and J. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993 999
12. M. Brune, M. Hansson, U.H. Mellqvist, S. Hermodsson, and K. Hellstrand NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites Eur J Haematol 57 1996 312 319
13. K. Hellstrand, S. Hermodsson, P. Naredi, U.H. Mellqvist, and M. Brune Histamine and cytokine therapy Acta Oncol 37 1998 347 353
14. A.I. Lanas, J.W. Anderson, N. Uemura, and B.I. Hirschowitz Effects of cholinergic, histaminergic, and peptidergic stimulation on pepsinogen secretion by isolated human peptic cells Scand J Gastroenterol 29 1994 678 683
15. T.B. Bury, J.L. Corhay, R. Louis, and M.F. Radermecker Decrease of T-lymphocyte proliferation in exercise-induced asthma Allergy 49 1994 605 610
16. Y. Lurie, F. Nevens, Z.G. Aprosina, T.A. Fedorova, A.V. Kalinin, and E.A. Klimova A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C J Viral Hepat 9 2002 346 353
17. T. Berg, M. von Wagner, H. Hinrichsen, T. Heintges, P. Buggisch, and T. Goeser Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1 Hepatology 38 2003 317A
18. M. Buti, A. Valdes, F. Sanchez-Avila, R. Esteban, and Y. Lurie Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases Hepatology 37 2003 1226 1227
19. J.M. Sanchez-Tapias, M. Diago, P. Escartin, J. Enriquez, R. Moreno, and M. Romero-Gomez Sustained virological response after prolonged treatment with peginterferon alfa-2a (40 KD) (Pegasys) and ribavirin (Copegus) in treatment-naive patients with chronic hepatitis C and detectbale HCV RNA after week 4 of therapy: Teravic-4 study J Hepatol 40 2004 150